Painless, Non-Invasive
Skin Cancer Therapy

Learn More

Bringing back Quality of Life

Non-Invasive
Painless
Single Session

Rhenium-SCT®

Non-Invasive
Painless
Aesthetic

The Rhenium-SCT (Skin Cancer Therapy) is a specialized state-of-the-art brachytherapy utilizing the radioisotope Rhenium-188, a beta-emitter which in this case is used for the treatment of basal and squamous cell carcinomas of the skin.

188W/188Re Generator

Production of high-energy beta emitting 188Re

Various sizes available

up to 150GBq (4Ci) 188W

High activity concentration

up to 9GBq/ml

Variable elution volume

Elution volume of 5-14 ml (partial elution for small volumes)

Low breakthrough

188W < 0.01 % in relation to 188Re at calibration time

Who we are

OncoBeta GmbH is a pioneer in the radioisotope sector, presently offering an innovative Skin Cancer Therapy targeting non-melanoma skin cancers and producing Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) Generators for commercial use.

Recent Events

B.J. Madan & Co India and OncoBeta announce exclusive distribution agreement for W/Re-188 generators.

B.J. Madan & Co India and OncoBeta announce exclusive distribution agreement for W/Re-188 generators.

New Delhi, India and Garching near Munich, Germany, 6th March, 2020. B.J Madan & Co and OncoBeta announced the execution...
Read More
RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada.

RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada.

RadioMedix and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.
Read More
Oncobeta chosen as one of the Trailblazing Companies to Watch in 2019

Oncobeta chosen as one of the Trailblazing Companies to Watch in 2019

OncoBeta- A Pioneer And Innovator In The Epidermal Radioisotope Therapy Sector Skin is the largest organ of the body and...
Read More
OncoBeta® receives Corporate Excellence Award 2019

OncoBeta® receives Corporate Excellence Award 2019

OncoBeta recognized as the Most Compassionate Skin Cancer Therapy Provider in 2019. OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), has recently been presented with the CV Magazine’s Corporate Excellence Award for the Most Compassionate Skin Cancer Therapy Provider in 2019.
Read More
First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Germany

First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Germany

The first Rhenium-SCT® treatment was accomplished by the interregional professional association for nuclear medicine in Hanau Dr. Lutz-Hendrik Holle, Medical Director of the interregional professional association for nuclear medicine in Hanau, has accomplished the first Rhenium-SCT® (Skin Cancer Therapy) treatment in Germany.
Read More
OncoBeta® chosen as a 2019 Red Herring North America Top 100 Winner

OncoBeta® chosen as a 2019 Red Herring North America Top 100 Winner

New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients. July 5, 2019;...
Read More
Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany

Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany

May 13 2019, Garching n. Munich, Germany– OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope...
Read More
OncoBeta ® GmbH Named Among ‘30 Ethical Companies of the Year 2019’ by The Silicon Review Magazine

OncoBeta ® GmbH Named Among ‘30 Ethical Companies of the Year 2019’ by The Silicon Review Magazine

Recognition for OncoBeta`s mission to give non-melanocytic skin cancer patients back their quality of life. April 05, 2019; Garching near...
Read More
OncoBeta® chosen as a 2019 Red Herring Top 100 Europe Winner

OncoBeta® chosen as a 2019 Red Herring Top 100 Europe Winner

Recognition of OncoBeta’s success in developing and providing an innovative therapy for patients suffering from non-melanocytic skin cancer Feb 20,...
Read More
OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe

OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe

Garching n. Munich, Germany, (January 10, 2019) – OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is proud to announce that it is listed as one of the Top 20 MedTech Solution Providers in Europe in 2018 by MedTech Outlook.
Read More